DaVita
DaVita is one of the two largest dialysis providers in the United States, operating 2,657 U.S. outpatient dialysis centers serving about 200,500 patients with end-stage kidney disease as of the end of 2025, plus 585 centers in 14 other countries. The company provides in-center hemodialysis, home dialysis, and related laboratory services, forming one half of a duopoly with Fresenius Medical Care that controlled roughly 77% of U.S. dialysis facilities as of 2019.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-24. Score revised 2026-09-24: 77 → 74.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
DLJ Merchant Banking bought the dialysis business from National Medical Enterprises in a leveraged buyout, founding Total Renal Care as a consolidation vehicle in a fragmented industry. It listed in 1995 and rolled up clinics quickly, then bought Renal Treatment Centers for $1.3 billion in 1998, an integration that overwhelmed the company. By July 1999 the CEO and CFO had resigned amid near-bankruptcy.
Kent Thiry became chairman and CEO in October 1999 and rebuilt the company, renaming it DaVita in 2000 and cutting staff turnover from about 52%. Growth resumed through targeted acquisitions from 2003. Beneath the recovery, a drug-wastage billing practice began at its clinics in 2003 that would later cost $495 million to settle.
The $3.1 billion Gambro Healthcare acquisition doubled DaVita's clinic count and left it and Fresenius with about 59% of U.S. facilities; the FTC required divestiture of 69 clinics and two management contracts across 35 markets. Separately billed drugs such as epoetin were a major profit center, and a 2007 JAMA study found for-profit chains gave the highest doses. DaVita used below-market joint-venture stakes and noncompetes to lock in physician referrals, a practice a whistleblower suit exposed in 2009.
Medicare's ESRD bundled payment ended separate drug billing, pushing DaVita to rely more on commercial payer mix. Berkshire Hathaway began buying shares, DaVita bought HealthCare Partners for $4.42 billion, and the duopoly kept absorbing independent clinics. Regulatory exposure grew with the $55 million Epogen overbilling settlement in 2012 and the $389 million physician-kickback settlement in October 2014.
The $495 million Medicare drug-wastage settlement in 2015 capped a run of federal payouts as DaVita leaned on buybacks and commercial payer mix. The American Kidney Fund premium-assistance model became a flashpoint: a 2017 securities suit alleged insurance steering, and DaVita disclosed that about 4,000 AKF-assisted commercial-group patients accounted for about $450 million of expected annual operating income. More settlements followed ($63.7 million for DaVita Rx in 2017, $270 million for DaVita Medical Group's Medicare Advantage coding in 2018), a Denver jury awarded $383.5 million over three patient deaths, and DaVita spent about $67 million to defeat California's 2018 Proposition 8.
After selling DaVita Medical Group to Optum for $4.3 billion, DaVita became a pure dialysis and kidney-care company and turned its cash into buybacks: about $3.85 billion in 2019-2020, $1.386 billion in 2024 and $1.788 billion in 2025, when its share count fell 14.9%. It spent $68 million and more than $52 million to defeat California's 2020 and 2022 dialysis measures, and in April 2026 won a 9th Circuit ruling striking AB 290's cap on AKF-assisted reimbursements. Scrutiny mounted from 2024 (FTC noncompete demands, SEIU-UHW strikes, a 2.7-million-person ransomware breach, a UFCW price-fixing suit, the MATCH-D class action and a Senate call for FTC action) but none has yet produced a finding against the company.
Alternatives
The only national, independent not-for-profit dialysis provider in the U.S., founded in 1971 and serving more than 14,000 patients at more than 240 locations with in-center and home dialysis. Research has found nonprofit dialysis facilities staff more registered nurses per patient than the large for-profit chains. The catch: its footprint is a small fraction of DaVita's, and as of 2019 about a third of Americans lived in areas where DaVita or Fresenius ran every facility, so DCI is only an option if one of its clinics or home programs serves your area and takes your insurance.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (66 events)
DLJ Merchant Banking Acquires Majority Stake via LBO
National Medical Enterprises spun off its dialysis subsidiary, Medical Ambulatory Care, in an August 1994 leveraged buyout led by DLJ Merchant Banking Partners and the unit's management, creating Total Renal Care Holdings with 37 outpatient facilities and 28 hospital inpatient contracts. The LBO-backed consolidation strategy set the template for rapid acquisition of independent dialysis clinics that would define the next three decades.
Total Renal Care IPO Raises $107 Million
Total Renal Care Holdings went public, raising $107 million. The IPO funded an aggressive acquisition spree that would grow the company from fewer than 40 facilities to nearly 500 within five years, establishing the rollup-consolidation business model.
Disastrous $1.3 Billion Acquisition of Renal Treatment Centers
Total Renal Care acquired Renal Treatment Centers for $1.3 billion in stock, doubling its patient and staff base overnight. The integration overwhelmed the company's billing systems — a 600-person billing office in Tacoma could not handle the expanded network. Accounts went uncollected, patients were billed incorrectly, and debt surged to $1.5 billion.
Rapid Clinic Rollup Creates Geographic Patient Lock-In
Through aggressive acquisitions of independent clinics, Total Renal Care grew from fewer than 40 facilities in 1994 to nearly 500 by the end of the decade. Because ESRD patients require thrice-weekly hemodialysis sessions lasting 3-4 hours each, they are effectively tied to the nearest facility within reasonable driving distance. As Total Renal Care absorbed independents, patients in acquired markets lost alternatives, creating de facto geographic lock-in even before the duopoly consolidated.
CEO and CFO Resign Amid Near-Bankruptcy
Total Renal Care chairman and CEO Victor Chaltiel announced he would step down in July 1999, and the CFO also resigned, as the company missed earnings expectations, defaulted on its loans and teetered near insolvency with about $1.5 billion in debt. Employee turnover was running near 50%, shareholders were suing, and the company was the target of SEC investigations. According to its 1999 annual report, its stock, which had closed as high as about $36 in 1998, closed as low as about $7 in the third quarter of 1999 and below $3 by March 2000; DaVita's own company history says it could barely make payroll when Kent Thiry took over.
Kent Thiry Appointed CEO, Begins Turnaround
Kent J. Thiry, a 43-year-old former Bain & Company consultant, was appointed CEO of the near-bankrupt Total Renal Care. Over the next five years he stabilized the company, cutting employee turnover from 52% to the low 20s, turning a $147 million loss (1999) into $222 million net income (2004), and growing revenue from $1.5 billion to $2.3 billion.
Company Rebrands to DaVita
More than 600 company leaders voted to rename Total Renal Care to DaVita, an Italian phrase meaning 'to give life.' The rebrand accompanied a cultural overhaul emphasizing values-based management and community identity, though the underlying business model of consolidation-driven growth remained intact.
Drug Wastage Fraud Scheme Begins at DaVita Clinics
Beginning in 2003, according to whistleblowers Dr. Alon Vainer and nurse Daniel Barbir, DaVita clinics administered the injectable drugs Zemplar and Venofer under mandatory 'dosing grids' and protocols designed to create unnecessary waste from single-use vials, then billed Medicare and Medicaid for the discarded portions. The alleged practice ran through 2010 and was resolved by a $450 million settlement in 2015.
DaVita Expands Through Targeted Acquisitions After Turnaround
DaVita's 1999 annual report said its acquisition growth had slowed sharply in the second half of 1999 and would remain limited in 2000 while it restructured its balance sheet. In July 2003 DaVita signed agreements to acquire RMS Lifeline, a network of 12 outpatient vascular access clinics, and RMS Disease Management from Baxter Healthcare. In September 2004 it completed the roughly $150 million purchase of Physicians Dialysis Inc., adding 24 centers and about 1,700 patients, the largest acquisition of Thiry's first five years. The steady purchase of independent operators continued to reduce local competition.
Gambro Acquisition Creates Dialysis Duopoly
DaVita acquired Gambro Healthcare, the third-largest U.S. dialysis provider with 565 clinics serving about 43,200 patients, for $3.1 billion. The deal effectively created a duopoly with Fresenius, with the two companies controlling roughly 59% of facilities. The FTC identified 35 local markets where competition would be lessened, 11 of which faced monopoly conditions, and required DaVita to divest 69 clinics and end two management contracts.
FTC Consent Order Requires 70-Clinic Divestiture
As a condition of the Gambro acquisition, DaVita divested 69 dialysis clinics and ended two management contracts across 35 markets to Renal Advantage. The order prohibited DaVita from soliciting divested clinic patients for two years and required FTC notification before any future acquisitions in affected markets. Despite divestitures, the deal cemented a duopoly structure.
JAMA Study: For-Profit Chains Give Highest Epoetin Doses as FDA Adds Black Box Warning
An April 2007 JAMA study of 159,522 Medicare hemodialysis patients (2004 data) found that patients at large for-profit dialysis chain facilities were consistently given the highest epoetin (Epogen) doses regardless of anemia status, an average of 3,306 more units per week than at nonprofit facilities. For-profit facilities also raised doses for patients already in the recommended hematocrit range. The study came weeks after the FDA added a boxed warning to erythropoiesis-stimulating agents over increased risk of death, heart attack and stroke at higher hemoglobin targets. Before Medicare's 2011 bundled payment, each dose was separately reimbursed.
DaVita Board Raises Share Repurchase Authorization to $250 Million
On May 1, 2008, DaVita's board authorized an additional $143.5 million of share repurchases, bringing the outstanding authorization to about $250 million; the company bought back 3.5 million shares for $169.7 million in the first half of 2008 under previously announced authorizations. Buybacks were already an established use of cash, and the buyback-centric capital allocation strategy would later consume billions annually. CEO Kent Thiry's total reported compensation reached $14.1 million in 2010, including about $4.76 million in stock awards and $4.73 million in option awards, according to DaVita's 2011 proxy statement.
Study Links Low RN Staffing in Dialysis Units to Skipped and Shortened Treatments
A 2008 Nephrology Nursing Journal survey of 422 staff nurses in chronic hemodialysis units found a mean of 9.58 patients per RN, with 31% of nurses caring for 12 or more patients. Patient-to-RN ratios of 12 or more were associated with significantly higher odds of frequently shortened and skipped dialysis treatments and patient complaints, linking nurse staffing levels in dialysis units to care quality.
Kickback Scheme to Physicians Exposed by Whistleblower
Former DaVita senior financial analyst David Barbetta filed a qui tam lawsuit alleging DaVita identified nephrologists with large patient populations, targeted 'winning' practices that were 'young and in debt,' and offered below-market joint venture stakes to lock in patient referrals. Noncompete agreements bound all physicians in a practice group, preventing them from directing patients elsewhere.
Medicare ESRD Bundled Payment System Takes Effect
CMS implemented the ESRD Prospective Payment System, bundling previously separate payments for drugs, labs, and supplies into a single per-treatment base rate of $229.63. Facilities could choose to be paid entirely under the new system from January 2011 instead of phasing in over four years, and most did. The reform shifted financial incentives, reducing the profitability of drug overuse but intensifying pressure to maximize commercial payer mix.
Berkshire Hathaway Begins Accumulating DaVita Shares
Ted Weschler, a Berkshire Hathaway portfolio manager, began building a large position in DaVita shares during Q4 2011. Berkshire would eventually accumulate over 45% of outstanding shares. In May 2013, Berkshire agreed to a standstill capping its stake at 25%, though this limit was later relaxed as DaVita's aggressive buyback program concentrated ownership.
No-Poach Agreements with Competitor Healthcare Companies Begin
Beginning as early as February 2012 and continuing until 2019, DaVita and CEO Kent Thiry allegedly entered into agreements with companies led by former DaVita executives, Surgical Care Affiliates and Hazel Health, and, as revealed at the 2022 trial, Radiology Partners, not to solicit each other's senior-level employees. The DOJ later charged these as criminal conspiracies to allocate employees; a jury acquitted DaVita and Thiry on all counts in 2022.
$55 Million Settlement for Epogen Overbilling
DaVita agreed to pay $55 million to settle a whistleblower lawsuit brought by former Amgen employee Ivey Woodard, which accused it of using more of the anemia drug Epogen than medically necessary and of billing the government for drug left over in vials. DaVita denied wrongdoing, and the government had declined to join the case. It was the first of three major whistleblower settlements between 2012 and 2015 that together approached $1 billion.
$4.42 Billion Acquisition of HealthCare Partners
DaVita acquired HealthCare Partners, the nation's largest operator of medical groups and physician networks, for $4.42 billion ($3.66 billion cash plus 9.38 million shares). The acquisition diversified DaVita into integrated care, creating DaVita HealthCare Partners Inc. The deal was partly funded by debt, adding leverage to an already capital-intensive business.
Study Finds For-Profit Dialysis Chains Staff Fewer Nurses per Patient
A 2013 American Journal of Kidney Diseases study of 4,800 U.S. hemodialysis facilities (2009 CMS survey data) found that, after adjustment, RN-to-patient ratios were 35% lower and LPN ratios 42% lower at for-profit facilities than at nonprofits, while patient care technician ratios were 16% higher. The large for-profit chains had significantly lower RN and LPN staffing than the largest nonprofit chain, substituting lower-cost technicians.
$389 Million Settlement for Physician Kickbacks
DaVita paid $389 million to resolve allegations that between 2005 and 2014 it paid kickbacks to nephrologists through below-market joint venture stakes to secure patient referrals. The DOJ found DaVita targeted 'winning' physician practices — those with large patient populations who were 'young and in debt' — and required noncompete agreements binding all group physicians regardless of their involvement.
$495 Million Settlement for Medicare Drug Wastage Fraud
DaVita agreed to pay $450 million, and set aside $45 million for attorney fees and costs, to settle a False Claims Act lawsuit alleging it billed Medicare and Medicaid for unused portions of Zemplar, Venofer, and other injectable drugs it threw away between 2003 and 2010. Whistleblowers Dr. Alon Vainer and nurse Daniel Barbir alleged DaVita created 'dosing grids' designed to maximize drug waste. This was DaVita's third major whistleblower settlement since 2012, bringing total payouts to nearly $1 billion.
Insurance Steering Lawsuit Alleges Charity-Funded Profit Loop
A securities class action filed by the Peace Officers' Annuity and Benefit Fund of Georgia alleged that DaVita inflated its results by steering Medicare- and Medicaid-eligible patients into commercial insurance, including ACA plans, and directing them to premium assistance from the American Kidney Fund, a charity DaVita heavily funded. AKF disclosed that nearly 80% of its donations over two years, about $396 million, came from two companies it did not name. According to the suit, commercial insurers paid DaVita about $4,000 per treatment versus $300 or less from government programs.
FTC Requires Seven-Clinic Divestiture in $358 Million Renal Ventures Acquisition
The FTC required DaVita to divest seven dialysis clinics, five in New Jersey (Brick, Clifton, Somerville, Succasunna, Trenton) and two near Dallas (Denton, Frisco), as a condition of its $358 million acquisition of Renal Ventures Management, the seventh-largest U.S. dialysis provider. In these markets the deal was a merger to monopoly or a reduction from three competitors to two. The FTC also barred DaVita from contracting with the divested clinics' medical directors for three years.
DaVita Fires Employee After Capitol Rally Speech on Patient Safety
DaVita fired a 16-year employee, patient care technician Emerson Padua, less than one day after he spoke at a May 23 rally at the California State Capitol in support of SB 349, the Dialysis Patient Safety Act, which proposed nurse-to-patient ratios of 1:8 and technician-to-patient ratios of 1:3. DaVita cited alleged policy violations. Three other employees at the same Riverside clinic were also fired, and SEIU-UHW filed an unfair labor practice charge. The bill was withdrawn later in 2017 amid insufficient support.
DaVita Discloses $450 Million Profit Tied to Charity-Paid Premiums
Under pressure over its American Kidney Fund ties, DaVita disclosed that fewer than 13% of its U.S. dialysis patients, about 25,000, received AKF support. About 4,000 of them had commercial group or COBRA premiums paid by the charity, and those patients accounted for roughly $450 million of DaVita's expected annual operating income. Another 1,800 AKF-assisted patients on individual plans were tied to $45-90 million.
DaVita Rx Pays $63.7 Million Over Improper Pharmacy Billing
DaVita's kidney-care pharmacy, DaVita Rx, agreed to pay $63.7 million to resolve False Claims Act allegations that it billed federal programs for drugs that were never shipped or were returned, and gave Medicare beneficiaries improper inducements such as waived copayments. The allegations came from self-disclosures and a whistleblower suit by two former employees.
Denver Jury Awards $383.5 Million Over Three Dialysis Deaths
A federal jury in Denver awarded families of three DaVita patients $383.5 million, including $125 million in punitive damages each, in wrongful-death suits over cardiac arrests linked to the GranuFlo acid concentrate used in DaVita clinics. Plaintiffs argued DaVita should have noticed rising bicarbonate levels in its patients. DaVita called the product safe and said it would appeal.
DaVita Medical Group Pays $270 Million Over Inflated Medicare Advantage Coding
DaVita Medical Holdings (formerly HealthCare Partners) agreed to pay $270 million to resolve False Claims Act allegations that it caused Medicare Advantage plans to receive inflated payments. The Justice Department said it issued improper coding guidance for a spinal condition and ran one-way chart reviews that added diagnoses but never removed unsupported ones.
DaVita Spends $67 Million to Defeat California Proposition 8
DaVita contributed approximately $67 million to defeat California Proposition 8, which would have capped dialysis clinic profits at 15% above patient care costs. Combined with Fresenius, the industry spent $111 million opposing the measure — a national record for ballot measure spending at the time. The proposition was defeated with 60% voting no.
CEO Transition: Rodriguez Succeeds Thiry After 20 Years
DaVita announced Javier J. Rodriguez as CEO effective June 1, 2019, succeeding Kent Thiry who had led the company since 1999. Rodriguez had been with DaVita since 1998 and served as CEO of DaVita Kidney Care since 2014. Thiry transitioned to executive chairman. The leadership change occurred as DaVita was refocusing on pure-play dialysis following the DaVita Medical Group sale.
DaVita Medical Group Sold to UnitedHealth for $4.3 Billion
Optum, a UnitedHealth Group subsidiary, completed its $4.3 billion acquisition of DaVita Medical Group, which managed physician networks and medical groups. The FTC required divestiture of HealthCare Partners of Nevada to Intermountain Healthcare, as the combined entity would have controlled over 80% of managed care provider services to Medicare Advantage insurers in Las Vegas. The sale refocused DaVita entirely on dialysis extraction.
JAMA Study Finds Large For-Profit Chains Waitlist Few Transplant Candidates
A JAMA study of 1.48 million U.S. dialysis patients from 2000 to 2016 found that patients at for-profit facilities were significantly less likely to be waitlisted for or receive a kidney transplant. The two for-profit chains with more than 1,000 facilities waitlisted 7.0% and 6.2% of patients, versus 29.8% at non-profit independent facilities.
Court Blocks California Law Capping Charity-Assisted Dialysis Payments
Governor Newsom signed AB 290 on October 13, 2019, capping what dialysis providers could collect for commercially insured patients whose premiums were paid by provider-funded charities. DaVita, Fresenius and the American Kidney Fund sued, and a federal court granted a preliminary injunction on December 30 before the law took effect. The bill's author said the injunction emboldened the Fresenius-DaVita duopoly.
DaVita Spends $68 Million to Defeat California Proposition 23
DaVita contributed approximately $68 million to defeat California Proposition 23, the second consecutive ballot measure seeking to regulate dialysis clinics. Prop 23 would have required a physician on-site during all treatment hours. Combined industry spending exceeded $105 million against the measure. It was defeated with 63% voting no.
DaVita Spends About $3.85 Billion on Buybacks in 2019-2020 After Medical Group Sale
After selling DaVita Medical Group for $4.3 billion in June 2019, DaVita spent about $2.4 billion repurchasing its stock in 2019, including a $1.23 billion Dutch auction tender offer, and about $1.45 billion in 2020, including a $705 million tender offer: roughly $3.85 billion over two years. As the share count shrank, Berkshire Hathaway's passive stake rose from 31.3% in March 2020 to 33.7% in March 2021 and 37.9% by March 2022 even though Berkshire had sold some shares, according to DaVita's proxy statements.
Court Approves $135 Million Settlement of Insurance-Steering Securities Suit
A federal court in Colorado granted final approval of the $135 million settlement of the 2017 shareholder class action alleging DaVita misled investors about revenue from patients whose premiums were paid by the American Kidney Fund. DaVita denied liability and said insurance covered most of the payment.
DOJ Indicts DaVita and Kent Thiry for No-Poach Conspiracy
A federal grand jury indicted DaVita Inc. and former CEO Kent Thiry under the Sherman Act for allegedly conspiring with other companies led by former DaVita executives, including Surgical Care Affiliates, not to solicit each other's senior-level employees between 2012 and 2019. The indictment charged two conspiracies, and a November 2021 superseding indictment added a third. It was the first time a company and a top executive were criminally charged over no-poach agreements.
FTC Imposes Prior Approval Requirements After Utah Acquisition
The FTC settled charges that DaVita's proposed acquisition of University of Utah Health's 18 dialysis clinics would reduce competition in the Provo, Utah market. DaVita had to divest three Provo-area clinics to Sanderling Renal Services, was barred from entering into or enforcing non-compete agreements that would keep University-employed physicians from working at competing clinics, and must obtain FTC prior approval before acquiring any dialysis clinic interest anywhere in Utah for ten years.
DaVita CEO's $73.4 Million 2020 Pay Tops Overpaid-CEO Ranking
An As You Sow ranking reported by Becker's put DaVita CEO Javier Rodriguez at the top among medical-group CEOs, with reported 2020 compensation of $73.4 million including a five-year equity grant. The report put his CEO-to-worker pay ratio at 1,137 to 1.
Jury Acquits DaVita and Thiry on All No-Poach Counts
A federal jury found DaVita and former CEO Kent Thiry not guilty on all counts in the DOJ's criminal no-poach prosecution after a two-week trial. DaVita's lawyers acknowledged that Thiry's behavior and language did not look great but argued that the agreements did not end meaningful competition. The verdict was a major setback for the DOJ's push to prosecute no-poach agreements criminally.
Supreme Court Rules Against DaVita in Marietta Dialysis Coverage Case
In a 7-2 decision, the Supreme Court held that an employer health plan offering the same limited outpatient dialysis coverage to all members does not violate the Medicare Secondary Payer statute, rejecting DaVita's disparate-impact claim. The ruling lets plans limit what they pay for dialysis, pushing patients toward Medicare sooner, which DaVita has since lobbied Congress to reverse.
DaVita Spends More Than $52 Million to Defeat Third California Ballot Measure
DaVita gave more than $52 million and Fresenius more than $27 million to defeat Proposition 29, the third consecutive California ballot measure targeting dialysis clinics. Prop 29 would have required a physician, nurse practitioner, or physician assistant on-site during treatment hours. Opposition committees spent more than $83 million, after raising more than $111 million against Prop 8 in 2018 and more than $105 million against Prop 23 in 2020.
D.C. Attorney General Investigates AKF Charity Connections
DaVita and Fresenius disclosed that the District of Columbia attorney general had opened an antitrust investigation concerning the American Kidney Fund. DaVita received a Civil Investigative Demand in January 2023 seeking its communications with AKF, records of donations to AKF, and communications with patients, providers and insurers about AKF. DaVita said the inquiry focused on a handful of D.C. clinics.
Congressional Press Conference Demands Dialysis Company Accountability
SEIU-UHW dialysis caregivers held a Capitol Hill press conference joined by Representatives Zoe Lofgren, Adam Schiff, and Katie Porter, asking lawmakers to investigate understaffing and labor practices at DaVita, Fresenius and Satellite Healthcare, companies holding large VA dialysis contracts (about $1.5 billion awarded to DaVita since 2014). A Fresenius dialysis technician said patient-to-worker ratios had risen from three-to-one to as many as eight or ten patients.
FTC Issues Two CIDs Investigating Dialysis Noncompetes
The Federal Trade Commission issued two Civil Investigative Demands to DaVita covering the period from January 2016 to present, seeking information about restrictive covenants and noncompete agreements with medical directors. The investigation focused on how noncompete clauses prevented nephrologists from joining competitors or establishing independent clinics, effectively blocking new market entrants.
DaVita Agrees to Buy Back Berkshire Shares to Hold Stake at 45%
DaVita signed a share repurchase agreement with Berkshire Hathaway under which, whenever DaVita's own buybacks push Berkshire's stake above 45%, DaVita must repurchase enough of Berkshire's shares each quarter to return it to 45%. The arrangement lets buybacks continue at scale without triggering a change of control.
$3.8 Million Settlement Over Facebook Pixel Patient Data Sharing
DaVita agreed to a $3.8 million settlement, preliminarily approved in July 2024, resolving class action claims that it shared website visitors' personal and health information with Facebook, Google and other third parties through tracking tools on its websites, patient portals and apps without consent. The class covers about 605,000 DaVita patients who used those platforms between November 2017 and September 2023. The court granted final approval after a December 16, 2024 hearing, according to the court-authorized settlement website.
$34 Million Kickback Settlement Filed by Former COO
DaVita paid $34.5 million to resolve False Claims Act allegations brought by former DaVita Kidney Care COO Dennis Kogod. The settlement addressed kickbacks to a competitor to refer Medicare patients' prescriptions to DaVita Rx, kickbacks to nephrologists for patient referrals, and improper payments to a nephrology practice including a $50,000 payment for a position the practice declined to staff.
Dialysis Caregivers Picket DaVita Clinics Across California
SEIU-UHW members picketed DaVita clinics over staffing shortages, patient care problems, and anti-union activity. Workers reported years of understaffing creating dangerous conditions for patients requiring life-sustaining treatment. DaVita had spent nearly $7 million on union-busting consultants from 2017-2020 and had reportedly closed at least one facility where organizing activity occurred.
Board Authorizes Additional $2 Billion in Share Repurchases
DaVita's board increased its share repurchase authorization by $2 billion. Repurchases can include buying shares from Berkshire Hathaway under an April 2024 agreement that requires DaVita to repurchase Berkshire's shares whenever Berkshire's stake exceeds 45%.
Workers at 37 California Dialysis Clinics, Including DaVita's, Launch Six-Day Strike
Nearly 900 healthcare workers at 37 DaVita, Fresenius, Satellite and U.S. Renal dialysis clinics across California began six-day unfair labor practice strikes on October 14, 2024. SEIU-UHW had filed 77 unfair labor practice charges against the four companies. Workers cited unsafe staffing, low wages, and anti-union retaliation; the union said DaVita had spent nearly $7 million on union-busting consultants from 2017 to 2020.
Ransomware Attack Exposes Data of 2.7 Million Patients
The Interlock ransomware group breached DaVita's network between March 24 and April 12, 2025, exfiltrating over 20 terabytes of data including 200+ million rows of patient records. Compromised information included names, SSNs, medical records, insurance details, and financial data for 2.7 million individuals. After ransom negotiations failed, according to the group, Interlock posted 1.5 terabytes of the stolen data on its leak site. The incident cost $13.5 million in Q2 2025.
UFCW Files Antitrust Class Action Alleging DaVita-Fresenius Collusion
The benefits fund for UFCW Local 1776 filed a class action in the U.S. District Court for the District of Colorado alleging DaVita and Fresenius conspired to allocate markets, protect supracompetitive profits, and collude with the American Kidney Fund to steer patients to lucrative private insurance. The suit claims prices 'would have been significantly lower' absent the conspiracy. DaVita and Fresenius moved to dismiss, arguing similar pricing is a natural outcome of concentration.
JAMA Study Confirms Dialysis Is Most Concentrated Healthcare Sector
A JAMA Health Forum study documented that between 2005 and 2019, DaVita and Fresenius increased their combined facility share from 59.1% to 77.1%, while independent centers declined from 20.4% to 10.6%. Markets with only one large chain had $495 higher average commercial prices and $565 higher medical director compensation per patient. The study concluded dialysis is 'the most concentrated of all health care sectors.'
Board Adds Another $2 Billion in Buyback Authority
DaVita's board increased its share repurchase authorization by $2 billion, on top of the amount remaining from the September 2024 authorization. Repurchases could be made in the open market or from Berkshire Hathaway under the 2024 agreement.
DaVita and Fresenius Move to Dismiss Price-Fixing Suit
DaVita and Fresenius Medical Care asked a federal judge in Colorado to dismiss the class action accusing them of fixing dialysis prices and dividing markets. They argued plaintiffs cited no specific price charged by either company and that the two compete extensively.
Class Action Alleges MATCH-D Quota Program Pressured Patients into PD
A class action filed by a California patient alleged DaVita used a quota-driven sales program called MATCH-D to push patients into home peritoneal dialysis regardless of suitability. The complaint says staff who missed quotas faced 'retaliation, intimidation, and humiliation.' The plaintiff said he was 'relentlessly bombarded' with exaggerated claims about PD, then suffered peritonitis infections and decreased transplant eligibility.
Senator Blumenthal Presses FTC on Dialysis Market Concentration
U.S. Senator Richard Blumenthal urged the FTC to take 'robust enforcement action' against DaVita and Fresenius, noting that the two companies control more than three-fourths of the dialysis market. He requested a briefing on the FTC's noncompete investigation opened in 2024, DaVita's compliance with its 2022 final order restricting acquisitions, and other antitrust issues in dialysis.
DaVita Spent $1.79 Billion on Buybacks in 2025, Above Free Cash Flow
DaVita's 2025 annual report showed it repurchased 12.7 million shares for $1.788 billion, a 14.9% net cut in its share count, against $1.024 billion of free cash flow. It also issued $1 billion of 6.75% senior notes during the year.
9th Circuit Strikes California's Cap on Charity-Assisted Dialysis Payments
The 9th Circuit held that AB 290's reimbursement cap and patient-disclosure provisions violate the First Amendment by burdening the American Kidney Fund's association with DaVita and Fresenius, while upholding a requirement that charities tell patients about all coverage options. DaVita said it was encouraged the law was found unenforceable, leaving the premium-assistance model intact in California.
Judge Denies Class Certification in No-Poach Employee Suit
A federal judge in Illinois declined to certify a class of more than 6,000 senior healthcare employees suing DaVita, Surgical Care Affiliates and United Surgical Partners over alleged no-poach agreements, finding individual questions would predominate. The ruling follows the 2022 criminal acquittal of DaVita and its former CEO.
Novi Clinic Closed After Patient Death and Hospitalizations
Oakland County, Michigan health officials asked DaVita to close its Novi dialysis center after a patient was found dead following treatment and several other patients were hospitalized; a second patient died in July. State inspectors found no significant protocol breach and the center reopened July 2, but records obtained by WXYZ showed repeated sanitation, maintenance and infection-control citations dating back to 2016.
Buybacks Continue With $751 Million in First Half of 2026
DaVita repurchased $403 million of stock in the first quarter and $348 million in the second quarter of 2026, while adding a $500 million incremental term loan in June. About $1.37 billion of repurchase authority remained at the end of July.
Court Preliminarily Approves $15 Million Ransomware Breach Settlement
A federal judge in Colorado preliminarily approved a settlement worth up to $15 million resolving class claims over DaVita's April 2025 ransomware attack, which exposed names, Social Security numbers, insurance and clinical data. Class members can claim up to $2,500 in documented losses or a pro rata cash payment, plus credit monitoring; a final approval hearing is set for February 2027 or later.
Evidence (55 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (9 entries)
List was empty with a duopoly reason. Added DCI, the national not-for-profit provider (dciinc.org: 14,000+ patients, 240+ locations), with a clear availability caveat drawn from the record's 32.5%-of-population figure; cleared alternativesReason since the list is no longer empty.
Checked 12 removed/trimmed claims: 2 restored, 7 partly restored, 3 confirmed removed, 0 already present. Restored: pixel settlement final approval (court-authorized settlement site via Wayback); $624,500 PAC-to-candidates figure (OpenSecrets summary via Wayback). Partly restored: 1999 stock collapse (1999 10-K405) and 'barely make payroll' (davita.com history); acquisitions limited in 2000 (1999 10-K405); Thiry 2010 pay $14.1M (2011 proxy, evidence added); Hazel Health and Radiology Partners in no-poach (Radiology Business, evidence added); Berkshire stake 31.3%->37.9% (2020-2022 proxies, evidence added); Amgen chart-access allegation re-attributed to the Woodard Epogen qui tam (McGuireWoods evidence added, not the Zemplar/Venofer item); Seeking Alpha evidence re-added with its real headline and date 2018-06-18. Confirmed removed: 2013 AKF placeholder item (duplicate; figures contradicted by Denver Post); 30% vs 80% DaVita/DCI hemoglobin figure; '60% of pre-tax profit' (4,000 patients/$450M already present as the Oct 2017 disclosure).
Checked 98 items + prose. 31 verified, 45 corrected (13 date-only), 19 re-sourced, 3 removed (1 duplicate, 1 unsupported, 1 unverifiable dead link). Invented: '60% of pre-tax profit' from AKF patients; DaVita-vs-DCI '30% vs 80%' hemoglobin figure; 'trained how to manipulate the system' and 'Amgen reps reviewed charts' in the drug-wastage event. Major fixes: 2019-2020 buybacks ($3.85B, not >$5B); lobbying $4.23M; D.C. AG probe 2023, not 2019; MATCH-D suit Nov 2025, not Jan 2025; strike covered four chains; Fresenius nurse's 15-patient quote misattributed to DaVita; 1999 loss $147M, not $417M.
77->74. D1 7->6 (recalibration: harms documented through union reports, allegations and one clinic investigation with no protocol breach found; no DaVita-specific above-benchmark infection, mortality or star-rating data for the 7+ band), D2 8->7 (correction: fact audit removed the invented '60% of pre-tax profit' AKF claim; real support is the $450M 2017 disclosure, 26%/11% payer mix and $495 single-chain premium, while steering remains unadjudicated and DaVita promotes home dialysis), D9 8->7 (recalibration: 254:1 pay ratio, union-avoidance spending and ULP strikes fit 6-7; no adjudicated whistleblower retaliation or layoffs-for-buybacks). D3 8, D4 9, D5 5, D6 7, D7 7, D8 9, D10 9 unchanged (2025 buybacks $1.788B above free cash flow and the April 2026 AB 290 win reinforce D3 and D10). Eras: 'Total Renal Care LBO' and 'Bundled Payment Shift' kept (summaries revised); 'Crisis & Turnaround' re-dated 1999-10-01->1999-10-18 (Thiry appointed) and relabeled 'Thiry Turnaround'; 'Gambro Duopoly Formation' re-dated 2005-10-01->2005-10-05 (Gambro close); 'Settlement & Buyback Era' re-dated 2015-06-01->2015-05-04 ($495M drug-wastage settlement); 'Pure-Play Extraction' re-dated 2019-06-01->2019-06-19 (Medical Group sale close) and merged with 'Regulatory Convergence' (dated 2026-02-16, an assessment date), since the 2024-26 scrutiny changed no scoring forces. All eras re-scored from criteria. Added 18 timeline events (11 historical gap-fills: 2017 AKF disclosure, 2017 DaVita Rx $63.7M, 2018 $383.5M GranuFlo verdict, 2018 $270M Medicare Advantage settlement, 2019 JAMA transplant study, 2019 AB 290 injunction, 2021 $135M securities settlement approval, 2020 $73.4M CEO pay, 2022 Marietta ruling, 2024 Berkshire repurchase agreement, 2025 $2B authorization) and 8 evidence items; D5 restored to 3 evidence items. Since Feb 2026: 2025 buybacks of $1.788B exceeded free cash flow and $751M more followed in H1 2026; the 9th Circuit struck AB 290's cap on AKF-assisted reimbursements (Apr 2026); the no-poach employee class was denied certification (Jun 2026); a Novi, MI clinic closed briefly after a patient death (Jun 2026); a $15M breach settlement won preliminary approval (Aug 2026); CEO pay ratio fell to 254:1; the FTC noncompete probe and UFCW price-fixing suit remain unresolved. Pixel settlement final approval still unconfirmed.
Triaged 2026-06-29; no rescore warranted (no material change since baseline, or changes sub-threshold).
Fixed Medicare rate ($239.33 was 2020 rate, updated to $271.02 CY 2024), Q1 2025 buybacks ($510M corrected to $550M), CA ballot spending ($143M corrected to $170M+)